Current Report Filing (8-k)
November 19 2020 - 06:02AM
Edgar (US Regulatory)
0001022079false00010220792020-11-182020-11-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of Earliest Event Reported):
November 18, 2020
Quest Diagnostics Incorporated
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
001-12215 |
|
|
16-1387862 |
(Commission File Number) |
|
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
500 Plaza Drive |
|
|
|
Secaucus, |
NJ |
|
|
07094 |
(Address of principal executive offices) |
|
|
(Zip Code) |
|
|
|
|
|
|
|
(973) |
520-2700 |
|
(Registrant's telephone number, including area code) |
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.01 Par Value |
DGX |
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01 Other Events
Quest Diagnostics Incorporated (the “Company”) has lifted the
temporary suspension, announced on April 22, 2020, of the Company’s
common stock repurchase program. As of November 18, 2020, $1.2
billion remained available under the Company’s share repurchase
authorization. The share repurchase authorization has no set
expiration or termination date.
Signature
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, hereunto duly
authorized.
November
18, 2020
QUEST DIAGNOSTICS INCORPORATED
By: /s/
William J. O'Shaughnessy, Jr.
William J. O'Shaughnessy, Jr.
Secretary
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Dec 2020 to Jan 2021
Quest Diagnostics (NYSE:DGX)
Historical Stock Chart
From Jan 2020 to Jan 2021